Quaiser A, Köhl U
Fraunhofer-Institut für Zelltherapie und Immunologie, Perlickstr. 1, 04103, Leipzig, Deutschland.
Institut für Klinische Immunologie, Universitätsklinikum Leipzig, Leipzig, Deutschland.
Internist (Berl). 2018 Dec;59(12):1230-1238. doi: 10.1007/s00108-018-0516-0.
Cell and gene therapy as part of immuno-oncology has reached an important milestone in medicine. After decades of experience stem cell transplantation is well established with worldwide >1 million transplantations to date. Due to the improved success of the last years using chimeric antigen receptor (CAR) T cells for CD19 positive leukemia and lymphomas, the interest in cellular therapies is continuously increasing. The current review also gives a short overview about donor lymphocytes, antigen-specific T cells, regulatory T cells, natural killer (NK) cells, mesenchymal stromal cells and induced pluripotent stem (iPS) cells in immuno-oncology.
作为免疫肿瘤学的一部分,细胞和基因疗法已在医学领域达到了一个重要的里程碑。经过数十年的经验积累,干细胞移植已得到广泛应用,迄今为止全球范围内已进行了超过100万例移植。由于近年来使用嵌合抗原受体(CAR)T细胞治疗CD19阳性白血病和淋巴瘤取得了更好的成效,人们对细胞疗法的兴趣持续上升。本综述还简要概述了免疫肿瘤学中的供体淋巴细胞、抗原特异性T细胞、调节性T细胞、自然杀伤(NK)细胞、间充质基质细胞和诱导多能干细胞(iPS细胞)。